Maxis VC

Maxis VC is an Istanbul-based institutional investor providing growth capital to scalable software and B2B technology startups emerging from the Turkish ecosystem, operating at seed and Series A with checks in the $250k to $1M range. AI is a stated focus, and healthcare interest centers on digital health and healthcare software. The fund occupies a credible mid-tier position in the Turkish venture stack, ranking alongside 212, Earlybird Digital East, and Revo Capital as one of the more active institutional early-stage players. The right founder for Maxis is a Turkish or CEE technical-commercial operator building B2B SaaS or AI-enabled software with healthcare as a vertical or wedge, with credible Turkish-market traction and realistic CEE, MENA, or European expansion logic. The wrong founder is a consumer health brand, a regulated medtech or therapeutics team, or a Series A-plus company looking for institutional lead. Intro paths run through Istanbul’s tight venture community, frequent co-investors including 212, Earlybird Digital East, Logo Ventures, and the StartersHub network, and through angels in the broader Turkish operator network including senior figures from Trendyol, Getir, Hepsiburada, and Peak Games. Direct outreach is read but warm intros materially help. In the pitch, lead with the founding team’s depth, real revenue and retention evidence, the unit economics in Turkish Lira with realistic FX assumptions, and a candid view of CEE and Western European customer acquisition dynamics if those are the expansion targets. Be specific about KVKK data protection compliance, Ministry of Health Turkey posture, and the difference between the SGK-dominated public payer reality and the growing private supplemental insurance segment. Show a credible plan to redomicile the holding company in Delaware, the UK, or the Netherlands if that has not already happened, since most Turkish-incorporated healthcare technology companies eventually need this structure for global capital raising. Caveats include the same Turkish macro and currency volatility issues that affect all funds in the country, the limited follow-on depth at Series B and beyond within the Turkish ecosystem, and the reality that Maxis’s check size is rarely sufficient as a sole lead at competitive Series A valuations. For Turkish healthcare software founders, Maxis is a credible institutional early partner that complements a multi-investor seed or Series A round.